Blood transfusion safety in the country of Georgia: collateral benefit from a national hepatitis C elimination program

Evan M. Bloch; Eteri Kipiani; Shaun Shadaker; Maia Alkhazashvili; Lia Gvinjilia; Tinatin Kuchuloria; Nazibrola Chitadze; Sheila M. Keating; Amiran Gamkrelidze; Alexander Turdziladze; Vladimer Getia; Muazzam Nasrullah; Francisco Averhoff; Mariam Izoria; Beth Skaggs

doi:10.1111/trf.15815

journal article May 04, 2020

Blood transfusion safety in the country of Georgia: collateral benefit from a national hepatitis C elimination program

Evan M. Bloch

Eteri Kipiani Shaun Shadaker

Maia Alkhazashvili

Lia Gvinjilia Tinatin Kuchuloria Nazibrola Chitadze Sheila M. Keating

Amiran Gamkrelidze Alexander Turdziladze Vladimer Getia Muazzam Nasrullah Francisco Averhoff

Mariam Izoria Beth Skaggs

Transfusion Vol. 60 No. 6 pp. 1243-1252 · Wiley

View at Publisher Save 10.1111/trf.15815

Abstract

BACKGROUNDIn April 2015, the government of Georgia (country) initiated the worldʼs first national hepatitis C elimination program. An analysis of blood donor infectious screening data was conducted to inform a strategic plan to advance blood transfusion safety in Georgia.STUDY DESIGN AND METHODSDescriptive analysis of blood donation records (2015‐2017) was performed to elucidate differences in demographics, donor type, remuneration status, and seroprevalence for infectious markers (hepatitis C virus antibody [anti‐HCV], human immunodeficiency virus [HIV], hepatitis B virus surface antigen [HBsAg], and Treponema pallidum). For regression analysis, final models included all variables associated with the outcome in bivariate analysis (chi‐square) with a p value of less than 0.05.RESULTSDuring 2015 to 2017, there were 251,428 donations in Georgia, representing 112,093 unique donors; 68.5% were from male donors, and 51.2% of donors were paid or replacement (friends or family of intended recipient). The overall seroprevalence significantly declined from 2015 to 2017 for anti‐HCV (2.3%‐1.4%), HBsAg (1.5%‐1.1%), and T. pallidum (1.1%‐0.7%) [p < 0.0001]; the decline was not significant for HIV (0.2%‐0.1%). Only 41.0% of anti‐HCV seropositive donors underwent additional testing to confirm viremia. Infectious marker seroprevalence varied by age, sex, and geography. In multivariable analysis, first‐time and paid donor status were associated with seropositivity for all four infectious markers.CONCLUSIONA decline during the study period in infectious markers suggests improvement in blood safety in Georgia. Areas that need further improvement are donor recruitment, standardization of screening and diagnostic follow‐up, quality assurance, and posttransfusion surveillance.

Topics

No keywords indexed for this article. Browse by subject →

References

37

[1]

WHO. Hepatitis C: key facts [monograph on the Internet]. 2018. Available from:https://www.who.int/news-room/fact-sheets/detail/hepatitis-c

[2]

10.7326/0003-4819-132-4-200002150-00008

[3]

10.1056/nejmoa1402355

[4]

10.1056/nejmoa1402454

[5]

10.1016/j.antiviral.2014.03.012

[6]

10.1093/cid/cir076

[7]

10.1001/jama.287.8.1043

[8]

10.1056/nejm200107053450107

[9]

10.15585/mmwr.mm6629a2

[10]

10.1007/s11524-006-9032-y

[11]

10.15585/mmwr.mm6829a2

[12]

10.1186/s12889-019-6784-3

[13]

10.15585/mmwr.mm6428a2

[14]

Ministry of Labour HaSA, National Center for Disease Control and Public Health (NCDC); US Centers for Disease Control and Prevention (2017)

[15]

10.1023/a:1015566132757

[16]

10.1016/j.tmrv.2007.03.001

[17]

10.1111/j.1537-2995.2009.02110.x

[18]

10.1001/jama.1970.03170020025005

[19]

10.1111/j.1423-0410.2007.01015.x

[20]

10.1182/blood-2018-11-833996

[21]

10.1016/j.tmrv.2011.07.006

[22]

10.1097/00000441-195903000-00003

[23]

10.1001/jama.220.5.692

[24]

10.1056/nejm196408132710702

[25]

WHO. Towards 100% voluntary blood donation: a global framework for action [monograph on the Internet]. Switzerland: WHO Press; 2010. Available from:https://www.who.int/bloodsafety/publications/9789241599696/en/

[26]

10.1111/trf.13773

[27]

10.1046/j.1537-2995.2002.00174.x

[28]

10.1186/s12985-016-0478-6

[29]

10.1002/hep.21413

[30]

10.3324/haematol.11224

[31]

10.1111/j.1537-2995.2008.01813.x

[32]

10.1111/trf.13891

[33]

10.1046/j.1537-2995.2002.00099.x

[34]

10.1053/tmrv.1997.0110155

[35]

10.1093/cid/ciz956

[36]

10.1128/cmr.8.1.1

[37]

10.1093/ije/dyt095

Metrics

13

Citations

37

References

Details

Published: May 04, 2020
Vol/Issue: 60(6)
Pages: 1243-1252
License: View

Authors

E

Evan M. Bloch

Johns Hopkins School of Medicine Baltimore Maryland USA

E

Eteri Kipiani

National Center for Disease Control and Public Health Tbilisi Georgia

S

Shaun Shadaker

Division of Viral Hepatitis National Center for HIV, Hepatitis, STD&TB Prevention Centers for Disease Control and Prevention Atlanta Georgia USA

M

Maia Alkhazashvili

National Center for Disease Control and Public Health Tbilisi Georgia

L

Lia Gvinjilia

South Caucasus Office of the U.S. Centers for Disease Control (CDC) Tbilisi Georgia

T

Tinatin Kuchuloria

South Caucasus Office of the U.S. Centers for Disease Control (CDC) Tbilisi Georgia

N

Nazibrola Chitadze

National Center for Disease Control and Public Health Tbilisi Georgia

S

Sheila M. Keating

Vitalant Research Institute (formerly Blood Systems Research Institute) San Francisco California USA; University of California San Francisco San Francisco California USA

A

Amiran Gamkrelidze

National Center for Disease Control and Public Health Tbilisi Georgia

A

Alexander Turdziladze

National Center for Disease Control and Public Health Tbilisi Georgia

V

Vladimer Getia

National Center for Disease Control and Public Health Tbilisi Georgia

M

Muazzam Nasrullah

Division of Viral Hepatitis National Center for HIV, Hepatitis, STD&TB Prevention Centers for Disease Control and Prevention Atlanta Georgia USA

F

Francisco Averhoff

Division of Viral Hepatitis National Center for HIV, Hepatitis, STD&TB Prevention Centers for Disease Control and Prevention Atlanta Georgia USA

M

Mariam Izoria

National Center for Disease Control and Public Health Tbilisi Georgia

B

Beth Skaggs

South Caucasus Office of the U.S. Centers for Disease Control (CDC) Tbilisi Georgia

Cite This Article

Evan M. Bloch, Eteri Kipiani, Shaun Shadaker, et al. (2020). Blood transfusion safety in the country of Georgia: collateral benefit from a national hepatitis C elimination program. Transfusion, 60(6), 1243-1252. https://doi.org/10.1111/trf.15815

Blood transfusion safety in the country of Georgia: collateral benefit from a national hepatitis C elimination program

You May Also Like